% | $
Quotes you view appear here for quick access.

VPHM Message Board

  • oinchats oinchats Jan 10, 2013 10:45 AM Flag


    ViroPharma target raised to $28 at WallachBeth (25.41)

    WallachBeth raises their VPHM tgt to $28 from $24. The firm notes, VPHM's 2013
    guidance looks aggressive, in particular relative to Cinryze revenue growth in
    US. The firm expects Cinryze revenue growth to decelerate from 28% yoy in 2012
    to 16% in 2013 as it becomes more difficult for the company to identify new
    HAE patients. Longer term, they continue to like the orphan drug story
    surrounding Cinryze and Plenadren. However, they believe high SG&A and R&D
    expenses will continue to pressure margins, resulting to less than 20% profit
    margin near term.